

Efficiency, prioritization, and vaccine portfolio optimization: Gavi policy

Maria Verykiou

Policy – Gavi, the Vaccine Alliance

mverykiou@gavi.org



IMMUNIZATION
ECONOMICS.ORG



Gavi 6.0

The Gavi model

Long-term funding

Pooling demand of lowest-income countries

Accelerating access to vaccines

Shaping markets for affordable vaccine products

Strengthening vaccine delivery platforms

Sustaining immunisation and transition




Market shaping

Donor base

Co-financing




Supply Demand



How Gavi supports countries: three key financing levers

57 countries
eligible for new
Gavi support in
2025



**Health system strengthening
support (\$2.4B*)**



**Vaccine
support (\$5.3B*)**





**Technical
assistance (\$1.2B*)**

*2021-2025 forecast expenditure excluding COVAX support

Accelerating access: growth of Gavi's vaccine portfolio

As of June 2024, Gavi supports vaccines against **20 infectious diseases** through **53 product presentations**

 Outbreak response



⁵ Notes:
¹ Diphtheria, tetanus, pertussis (DTP), hepatitis B, Haemophilus influenzae type b (Hib).
² The Vaccine Investment Strategy (VIS) did not recommend continuing COVID-19 in Gavi's portfolio from 2026.
³ Respiratory syncytial virus (RSV) vaccine was approved in principle through the Vaccine Investment Strategy 2018.



Gavi 6.0 strategy one-pager (2026 – 2030)

VISION

Leaving no one behind with immunisation



MISSION

To **save lives** and **protect people's health** by increasing **equitable and sustainable use of vaccines**

PRINCIPLES

- Country-led, sustainable
- Community-owned, inclusive
- Zero-dose and missed communities
- Gender-focused
- Differentiated, fragile-responsive
- Integrated
- Adaptive, resilient
- Climate-sensitive
- Innovative
- Collaborative, accountable

GOALS

1 INTRODUCE AND SCALE UP VACCINES

2 STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION

3 IMPROVE PROGRAMMATIC AND FINANCIAL SUSTAINABILITY OF IMMUNISATION PROGRAMMES

4 ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS


ENABLERS

- Long-term predictable funding
- One Alliance
- Global political commitment
- Simple, efficient and agile Gavi operating model
- Digitalisation, improved data and evidence
- Collaboration with private sector and development finance institutions

Strategic goal 1: key priorities

Strategic goal	Area	Priority interventions
1 INTRODUCE AND SCALE UP VACCINES	New vaccine introductions	<ul style="list-style-type: none">• Scaling up routine introductions; accelerating access to new vaccines• Targeted support for ‘traditional’ vaccines in fragile & humanitarian settings• Stronger prioritisation and optimisation of countries’ vaccine portfolios
	Campaigns	<ul style="list-style-type: none">• Improve vaccination campaign effectiveness
	Outbreaks, epidemics, pandemics	<ul style="list-style-type: none">• Expanded stockpiles access for outbreak response• First Response Fund for major public health emergencies

Gavi Gavi 6.0 strategy: Vaccine Portfolio Optimisation and Prioritisation



Savings on optimization have the potential to facilitate NVIs and/or programme expansion

WHY

- Countries face **expanding vaccine portfolios** & competing priorities amid **reduced** global health **funding**.
- **Fragmented efforts** across partners cause **gaps, inconsistent data, and uneven country capacity**.
- Promote **sustainable** immunization and **maximize impact** through domestic investment and evidence-based decisions.

HOW

- ✓ Streamline **coordination with a unified framework** integrated into NIS and Gavi application processes.
- ✓ Enable **data-driven prioritization** through curated **evidence and analytical tools** for strategic funding decisions.
- ✓ Strengthen country decision-making with **enhanced tools, capacity building, and cross-sectoral engagement**.

* e.g., NVIs, increasing coverage of existing programmes or campaigns.

Strategic goal 4: key priorities

Strategic goal	Area	Priority interventions
4 ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS	Healthy markets & delivery innovations	<ul style="list-style-type: none">• Shape markets including for fully self-financing countries post-transition• Countries incentivised to focus on vaccine portfolio optimisation• Access to vaccine delivery innovations
	Regional vaccine supply security	<ul style="list-style-type: none">• Address supply security challenges by supporting diversified regional supply bases – <i>for example, via the African Vaccine Manufacturing Accelerator (AVMA)</i>
	Outbreak prevention	<ul style="list-style-type: none">• Improved market conditions for vaccines against outbreak-, epidemic- and pandemic-prone diseases

VPOP under Gavi 6.0 as part of the Health Systems Strategy *(under development)*

PILLAR			
Foundations & Strategy	Capacity Strengthening & Alignment	Implementation Support	Monitoring & Evaluation
STRATEGIC PURPOSE			
<ul style="list-style-type: none"> • Cohesive vision • Global public goods & normative guidance • Country-owned decision-making • Market shaping goals 	<ul style="list-style-type: none"> • Strengthened local and regional capacity to apply VPOP 	<ul style="list-style-type: none"> • Targeted, hands-on technical assistance • Coordination mechanisms 	<ul style="list-style-type: none"> • Progress and accountability through data, learning, and adaptation • Continued monitoring of risks (market health and access)
ACTIVITIES			
<i>Advocacy, global guidance (e.g., SAGE), tools like NVI-PST and WHO Data Compendium, GNN support</i>	<i>Regional trainings, capacity building and institutionalization of VPOP knowledge, partner alignment</i>	<i>In-country technical assistance, continued NITAG strengthening, agency coordination, SOPs</i>	<i>Indicators, dashboards, case studies, peer learning</i>

Alliance support for Vaccine Portfolio Optimisation & Prioritisation (VPOP)



Development Catalysts



World Health
Organization

Gates
Foundation

Introduction to VPOP

Prioritisation & optimisation as solutions



Vaccine prioritisation:

Deciding which vaccine programmes* to invest in, and in what order, under limited capacity and resources (*e.g. malaria vs HPV introductions*).



Vaccine Optimisation:

Assessing new products, presentations, schedules, or uses and switch to more opportune ones (*e.g. PCV*).

The impact of successful VPOP

At country-level

- **Planned** future vaccine introductions with **programmatic, financial, and synergy** considerations
- **Evidence**-informed decision-making **process**, aligned with **national priorities**

At global-level

- Country preferences **informed global strategies**, enabled **shared learning**, and helped anticipate and **mitigate supply risks**
- The **Lusaka Agenda** : **one plan, one budget, one report**

* e.g. NVIs, increasing coverage of existing programmes or campaigns.

VPOP in an evolving landscape

A New Approach to a Longstanding Need

A new **Alliance-led working group (WG)** to support countries in **vaccine prioritisation and optimization** to meet growing country demand for faster, with more flexible tools and a streamlined, partner-aligned and coordinated approach.

Adapting to an Evolving Environment

We are operating in a **context with limited predictability**:


- **National**: declining ODA and financing ; limited visibility on future support
- **Regional and global**: uncertainty around future resources and sustained support.


Supporting the Transition: Prioritisation to Optimisation

Shift from prioritisation to optimization:


- Emphasis on efficiency and cost-saving has increased the focus on optimising vaccine portfolios. **Need to support countries in navigating this shift.**

The impact of countries decision making on portfolio optimisation and prioritisation of future NVI have different time horizons

<i>NIS (3-5 years)</i> 			
Country	Portfolio optimisation	NVI prioritisation	
	Primary focus	Maximizing the impact, efficiency, and coverage of already introduced vaccines	Selecting and planning for the introduction of new vaccines in a systematic, evidence-informed way
	Time horizon	Short to medium term	Medium to longer term
		Immediate adjustments for program performance	Planning for vaccine introduction in next 3–5y
	Benefits	Cost savings and supply security through product choice and schedule change	Health system readiness, data generation, research agenda, supply allocation, workforce capacity
		Programmatic improvements (e.g. wastage, delivery models, dosing schedules)	Financially sustainable vaccines
		Led by EPI (may not require NITAG recommendation)	Led by NITAG

<i>Gavi 6.0</i> 		
Global	Short to medium impact on global vaccine portfolio supported by Gavi (products, volumes and total cost)	Anticipate future evolution of Gavi programmes through improved understanding of countries' future priorities

Improved coordination across partners to support country decision-making



An Alliance approach – Progress to date

Key achievements & milestones

Early adopters

- **Countries have used different MCDA approaches including the WHO CAPACITI decision support tool** (e.g., Thailand, Bangladesh, China, Korea, Indonesia), a NITAG tailored tool is getting traction from countries (NVI PST)
- VPOP responds to this demand with **faster, more flexible tools and a streamlined, partner-aligned process** (piloted in DRC, Uganda, Guinea Bissau, Niger), using NVI PST.
- **Designed to be integrated within national planning cycles** like NIS and grant applications.
- Countries continue to request TA and support to review their vaccine portfolios, prioritise and optimise.


Capacity strengthening & training

- Training of Trainers and regional NITAG workshops to **build local capacity**.
- **Sensitization** of NITAGs, EPI Managers, and other stakeholders via GNN, WHO regional meetings, and webinars (AFRO, EMRO, SEARO).

Advocacy & stakeholder engagement

- Momentum through GNN and its partners
- Featured at **SAGE** (March 2025)
- Integrated into **Gavi 6.0** through Health Systems Strategy, Foundations Fund, SG1a indicator, and NIS guidance.

Partners already supporting country requests



Learnings to date indicate that **models for technical assistance** will vary depending on countries needs.

Partner contributions


Core Alliance Partners (Gavi, WHO, UNICEF) leveraging expanded partners

- Adapted tools and global guidance to country needs
- Built on SAGE recommendation, through GNN to drive VPOP momentum
- Engagement of regional and country stakeholders to build capacity
- Funded technical assistance, funded pilots and learning

Coordination via VPOP Working Group with PMU support

- Coordinated response to countries requests, aligned partner efforts for country support
- Developed key tools like risk assessments
- Mapped strategic opportunities and risks

Alignment with Market Health - Optimisation



Gap: *There is currently no formal incentive for countries to engage in optimisation, despite growing pressure to improve efficiency and identify market savings.*

Vaccine portfolio optimisation: available switches of product, presentation or schedule

Vaccine	Product/ Presentation	Schedule
HPV	4 products options	Shift to a single dose schedule
PCV	3 product options (+ 1 submitted for PQ)	Adapted schedule pending SAGE recommendation
Rota	6 product options	
Penta + IPV / Hexavalent	Presentation options for Penta and IPV	Switch to 3 dose Hexavalent schedule, from 3 Penta + 2 IPV
Measles-containing	Presentation switch from 10 to 5 doses/vial Switch from M to MR	Switch to MCV 2
Yellow Fever	Presentation switch from 10 to 5 doses/vial	
Meningitis	Replacement of Men A with Men5CV (Men ACYWX)	

Assessment criteria to consider

- **Delivery and ease of use:** efficacy and safety, number of injections, schedule changes, administration complexity for HCW.
- **Supply/cold chain:** wastage, cold chain volume, shelf life, VVM type
- **Supply availability and security**
- **Vaccine procurement and delivery costs**

Lessons learned to date



Lessons learned & best practices



Importance of **data, bandwidth, and support structures** to strengthen NITAGs and EPI teams to review optimization decisions.



High demand for **streamlined guidance** from countries to manage multiple sources of information



VPOP support must be adaptable to fluctuating country contexts and timelines.




Integration of **VPOP** into existing national processes and structure (e.g. NIS).



Country vaccine choices can collectively influence market dynamics, highlighting the continued importance of a coordinated global role for **healthy markets and sustainable vaccine programs**.

VPOP Workplan 2025



Interdependencies with 6.0 operationalization:

Process shifts

- Grant cycle alignment and consolidated grants
- Revised partnerships model and TA support

Potential strategic shifts


- Gavi 6.0 replenishment and recalibration
- Country vaccine envelopes



Discussion

- Feedback on Gavi 6.0 strategy for increasing country ownership and support in vaccine prioritization and optimisation through the application process?
- What are key inputs in terms of evidence to inform and guide this process that Gavi can support?

Gavi Gavi 6.0 strategy: Vaccine Portfolio Optimisation and Prioritisation



Savings on optimization have the potential to facilitate NVIs and/or programme expansion

WHY

- Countries face **expanding vaccine portfolios** & competing priorities amid **reduced** global health **funding**.
- **Fragmented efforts** across partners cause **gaps, inconsistent data, and uneven country capacity**.
- Promote **sustainable** immunization and **maximize impact** through domestic investment and evidence-based decisions.

HOW

- ✓ Streamline **coordination with a unified framework** integrated into NIS and Gavi application processes.
- ✓ Enable **data-driven prioritization** through curated **evidence and analytical tools** for strategic funding decisions.
- ✓ Strengthen country decision-making with **enhanced tools, capacity building, and cross-sectoral engagement**.

* e.g., NVIs, increasing coverage of existing programmes or campaigns.

Thank you



IMMUNIZATION
ECONOMICS.ORG